- Home
- ZYME vs WRLD Comparison
ZYME vs WRLD Comparison
Compare ZYME & WRLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZYME
- WRLD
- Stock Information
- Founded
- ZYME 2003
- WRLD 1962
- Country
- ZYME United States
- WRLD United States
- Employees
- ZYME N/A
- WRLD N/A
- Industry
- ZYME Biotechnology: Pharmaceutical Preparations
- WRLD Finance: Consumer Services
- Sector
- ZYME Health Care
- WRLD Finance
- Exchange
- ZYME Nasdaq
- WRLD Nasdaq
- Market Cap
- ZYME 751.6M
- WRLD 690.7M
- IPO Year
- ZYME 2017
- WRLD 1991
- Fundamental
- Price
- ZYME $15.39
- WRLD $116.63
- Analyst Decision
- ZYME Buy
- WRLD
- Analyst Count
- ZYME 5
- WRLD 0
- Target Price
- ZYME $19.00
- WRLD N/A
- AVG Volume (30 Days)
- ZYME 572.6K
- WRLD 20.5K
- Earning Date
- ZYME 10-31-2024
- WRLD 10-25-2024
- Dividend Yield
- ZYME N/A
- WRLD N/A
- EPS Growth
- ZYME N/A
- WRLD 57.43
- EPS
- ZYME N/A
- WRLD 14.74
- Revenue
- ZYME $62,199,000.00
- WRLD $557,739,360.00
- Revenue This Year
- ZYME $30.09
- WRLD N/A
- Revenue Next Year
- ZYME N/A
- WRLD $0.78
- P/E Ratio
- ZYME N/A
- WRLD $7.91
- Revenue Growth
- ZYME N/A
- WRLD N/A
- 52 Week Low
- ZYME $7.80
- WRLD $101.85
- 52 Week High
- ZYME $17.70
- WRLD $149.31
- Technical
- Relative Strength Index (RSI)
- ZYME 55.74
- WRLD 47.21
- Support Level
- ZYME $12.39
- WRLD $121.23
- Resistance Level
- ZYME $17.70
- WRLD $124.88
- Average True Range (ATR)
- ZYME 0.84
- WRLD 3.06
- MACD
- ZYME 0.10
- WRLD -0.12
- Stochastic Oscillator
- ZYME 56.50
- WRLD 28.69
About ZYME Zymeworks Inc.
Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated product candidates. Its clinical candidate, zanidatamab, is a novel Azymetric HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. The company is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.
About WRLD World Acceptance Corporation
World Acceptance Corp operates a small-loan consumer finance business. The company offers short-term small installment loans, medium-term larger installment loans, related credit insurance and ancillary products and services to individuals. It also offers income tax return preparation services to its loan customers and other individuals.